You are here

MEK inhibitor

Wistar Researchers Find Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma

CP Wire

Thu, 04/12/18 - 11:59 am

Wistar Institute

Wistar Researchers Find Combination Therapy Effective for NRAS Mutant and Therapy Resistant Melanoma

Thu, 04/12/18 - 11:56 am

How Far Into the Drug Pipeline Should the FTC Reach?

TheStreet.com

Mon, 05/1/17 - 10:59 am

Array Biopharma

Novartis AG wins approval to buy GSK cancer drugs with conditions

Yahoo/Reuters

Mon, 02/23/15 - 06:00 pm

GlaxoSmithKline Begins Phase 3 Melanoma Study

Motley Fool

Mon, 02/4/13 - 11:24 am

Exelixis: First Partnered Program Enters Phase III

Seeking Alpha

Wed, 10/3/12 - 11:20 am